Department of Medicine, University of Toronto, University Health Network, Toronto, Ontario, Canada.
Section of General Internal Medicine, Lakeridge Health Oshawa, Oshawa, Ontario, Canada.
JAMA. 2014 Jun 18;311(23):2422-31. doi: 10.1001/jama.2014.5552.
Thoracentesis is performed to identify the cause of a pleural effusion. Although generally safe, thoracentesis may be complicated by transient hypoxemia, bleeding, patient discomfort, reexpansion pulmonary edema, and pneumothorax.
To identify the best means for differentiating between transudative and exudative effusions and also to identify thoracentesis techniques for minimizing the risk of complications by performing a systematic review the evidence.
We searched The Cochrane Library, MEDLINE, and Embase from inception to February 2014 to identify relevant studies.
We included randomized and observational studies of adult patients undergoing thoracentesis that examined diagnostic tests for differentiating exudates from transudates and evaluated thoracentesis techniques associated with a successful procedure with minimal complications.
Two investigators independently appraised study quality and extracted data from studies of laboratory diagnosis of pleural effusion for calculation of likelihood ratios (LRs; n = 48 studies) and factors affecting adverse event rates (n = 37 studies).
The diagnosis of an exudate was most accurate if cholesterol in the pleural fluid was greater than 55 mg/dL (LR range, 7.1-250), lactate dehydrogenase (LDH) was greater than 200 U/L (LR, 18; 95% CI, 6.8-46), or the ratio of pleural fluid cholesterol to serum cholesterol was greater than 0.3 (LR, 14; 95% CI, 5.5-38). A diagnosis of exudate was less likely when all Light's criteria (a ratio of pleural fluid protein to serum protein >0.5, a ratio of pleural fluid LDH to serum LDH >0.6, or pleural fluid LDH >two-thirds the upper limit of normal for serum LDH) were absent (LR, 0.04; 95% CI, 0.02-0.11). The most common complication of thoracentesis was pneumothorax, which occurred in 6.0% of cases (95% CI, 4.0%-7.0%). Chest tube placement was required in 2.0% of procedures (95% CI, 0.99%-2.9%) in which a patient was determined to have radiographic evidence of a pneumothorax. With ultrasound, a radiologist's marking the needle insertion site was not associated with decreased pneumothorax events (skin marking vs no skin marking odds ratio [OR], 0.37; 95% CI, 0.08-1.7). Use of ultrasound by any experienced practitioner also was not associated with decreased pneumothorax events (OR, 0.55; 95% CI, 0.06-5.3).
Light's criteria, cholesterol and pleural fluid LDH levels, and the pleural fluid cholesterol-to-serum ratio are the most accurate diagnostic indicators for pleural exudates. Ultrasound skin marking by a radiologist or ultrasound-guided thoracentesis were not associated with a decrease in pneumothorax events.
胸腔穿刺术用于确定胸腔积液的病因。尽管一般安全,但胸腔穿刺术可能会出现短暂性低氧血症、出血、患者不适、复张性肺水肿和气胸等并发症。
通过系统评价证据,确定区分渗出液和漏出液的最佳方法,并确定胸腔穿刺术技术,以最大程度地降低并发症风险。
我们检索了 Cochrane 图书馆、MEDLINE 和 Embase,从开始到 2014 年 2 月,以确定相关研究。
我们纳入了接受胸腔穿刺术的成年患者的随机和观察性研究,这些研究检查了用于区分渗出液和漏出液的诊断试验,并评估了与成功手术相关的胸腔穿刺术技术,以最小化并发症风险。
两名调查员独立评估研究质量,并从胸腔积液实验室诊断研究中提取数据,以计算似然比(LR;n=48 项研究)和影响不良事件发生率的因素(n=37 项研究)。
如果胸腔液中的胆固醇大于 55mg/dL(LR 范围,7.1-250)、乳酸脱氢酶(LDH)大于 200U/L(LR,18;95%CI,6.8-46)或胸腔液胆固醇与血清胆固醇的比值大于 0.3(LR,14;95%CI,5.5-38),则渗出液的诊断最为准确。如果所有 Light 标准(胸腔液蛋白与血清蛋白之比>0.5、胸腔液 LDH 与血清 LDH 之比>0.6 或胸腔液 LDH 大于血清 LDH 正常值的三分之二)均不存在,则渗出液的诊断可能性较小(LR,0.04;95%CI,0.02-0.11)。胸腔穿刺术最常见的并发症是气胸,占 6.0%(95%CI,4.0%-7.0%)。如果确定患者有放射影像学证据显示气胸,则 2.0%(95%CI,0.99%-2.9%)的手术需要放置胸腔引流管。如果放射科医生标记针插入部位,使用超声并不会降低气胸事件的发生(皮肤标记与无皮肤标记比值比 [OR],0.37;95%CI,0.08-1.7)。任何有经验的医生使用超声也不会降低气胸事件的发生(OR,0.55;95%CI,0.06-5.3)。
Light 标准、胆固醇和胸腔液 LDH 水平以及胸腔液胆固醇与血清胆固醇的比值是胸腔渗出液最准确的诊断指标。放射科医生进行超声皮肤标记或超声引导下的胸腔穿刺术与气胸事件的减少无关。